Elanco Animal Health (NYSE:ELAN) Releases FY 2026 Earnings Guidance

Posted by Francis Steltz on Nov 7th, 2026

Elanco Animal Health (NYSE:ELAN – Get Free Report) issued an update on its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 1.170-1.200 for the period, compared to the consensus estimate of 1.130. The company issued revenue guidance of $5.2 billion, compared to the consensus revenue estimate of $5.1 billion. Elanco Animal Health also updated its Q4 2026 guidance to 0.160-0.190 EPS.

Elanco Animal Health Stock Up 8.3%

Shares of NYSE ELAN opened at $25.65 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. Elanco Animal Health has a 52 week low of $19.40 and a 52 week high of $27.98. The stock’s fifty day moving average is $23.13 and its 200 day moving average is $23.82. The stock has a market capitalization of $12.81 billion, a P/E ratio of -62.55, a PEG ratio of 2.14 and a beta of 1.73.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.07. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.21 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Sell-side analysts forecast that Elanco Animal Health will post 1.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ELAN has been the topic of several research reports. Morgan Stanley decreased their price target on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 29th. UBS Group boosted their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. The Goldman Sachs Group began coverage on Elanco Animal Health in a report on Friday, October 16th. They set a “buy” rating and a $32.00 price objective on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, September 30th. Finally, Jefferies Financial Group downgraded shares of Elanco Animal Health from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $31.00 to $24.00 in a report on Tuesday, October 20th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.33.

View Our Latest Stock Analysis on ELAN

Insider Activity

In other news, insider Timothy Bettington sold 4,350 shares of Elanco Animal Health stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $23.00, for a total transaction of $100,050.00. Following the transaction, the insider owned 138,911 shares in the company, valued at approximately $3,194,953. The trade was a 3.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Harrington bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were acquired at an average price of $21.82 per share, with a total value of $109,100.00. Following the acquisition, the director owned 131,451 shares of the company’s stock, valued at $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 48,998 shares of company stock valued at $1,139,373. Company insiders own 1.14% of the company’s stock.

More Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.